Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in Familial Pulmonary Fibrosis and Interstitial Lung Abnormalities (DROP-FPF)
NCT07201922Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2026
- Primary completion
- May 2029
- Countries
- 13
01
Overview
A Phase 3 trial of nerandomilast in pulmonary fibrosis (PF), interstitial lung disease (ILD), sponsored by Boehringer Ingelheim. Started Feb 2026; status: recruiting.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07201922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07201922.